Endocrine cancer pancreas prognosis
Endometrial cancer diagnostic tests Abstract The neuroendocrine tumors NETs are more frequent during the last decades. One of the major tools to evaluate this type of pathology is the neuroendocrine markers as chromogranin A, serotonin, urinary 5-hydroxy indolacetic acid, and neuron specific enolase.
They change endocrine cancer pancreas prognosis to the disease progression, regardless therapy. Some of the drugs that are used for NETs as somatostatin analogs for example octreotide might interfere with glucose metabolism. We analyzed in a retrospective study of 2 years the dynamic of the NET markers and the glycemia profile.
Revista Societatii de Medicina Interna
Material and Methods. All the patients had at least one assay per year. The dose of octreotide varied from 20 to 50 mg, monthly.
The fasting glucose insignificantly changed from baseline after 2 years.
No new case of diabetes was endocrine cancer pancreas prognosis. One case of known diabetes needed insulin but interferon therapy was also added during this time period.
The chromogranin A had sustained high values for all the 9 cases, marking the disease progression.
The incidence of GEP-NENs has increased worldwide over the past decades, with the small intestine, rectum, and pancreas as the most common tumor locations. The epidemiological characteristics, pathogenesis and treatment have raised many questions, and some of them are still being debated.
The neuron specific enolase significantly increased, and the serum serotonin as well as the 5HIIA was much higher in 2 cases with aggressive carcinoid symptoms. The NET markers and the glucose metabolism are most useful tools in the management of NETs, yet they are not correlated. Neuroendocrine tumors. Endocr Relat Cancer. DOI: Oberndorfer S.
- Cancerul osos este ereditar
Воздушный шлюз беззвучно закрылся за ним, когда он покинул корабль.
- Markeri imunohistochimici în diagnosticul diferenţial al tumorilor pancreatice
- Oxiuros que puedo tomar
- Ce inseamna metale grele
Karzinoide tumoren des dunndarms. Frank Z Pathol.
AJCC Cancer Staging Manual: Mahul B. Amin · | Books Express
Carcinoid Tumors. Bellizzi AM. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnosis immunohistochemistry.
Rogoveanu2, T. Ciurea2, Larisa Săndulescu2, A. Scopul studiului a fost identificarea unor markeri de diagnostic precoce şi prognostic evolutiv în cancerul pancreatic. Examenul citologic standard a inclus la toţi cei 38 de pacienţi 2 frotiuri colorate May-Grunwald-Giemsa şi 2 frotiuri colorate Papanicolau.
Adv Anat Pathol. Chromogranins A B C: widespread consitituents of secretory vesicles. Endocrine cancer pancreas prognosis N Y Acad Sci.
Побывали ли в Диаспаре эмиссары Лиза, чтобы провести манипуляции с мозгом Хедрона.
- Cancer limfatic ce inseamna
Четкость была изумительной, почти неестественной, хотя масштаб оставлял впечатление нормального, без дополнительного увеличения.
- Anomalie frottis papillomavirus
- Enterobius vermicularis autoinfection
Chromogranin A neuron specific enolase carcinoembryonic antigen and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. CO; 8. Regul Pept. The poor prognosis factors in G2 neuroendocrine tumor. Rom J Morphol Embryol.
The dedifferentiation of neuroendocrine tumor metastases: myth or reality? Octreotide for the treatment of hypoglycemia after insulin glargine overdose. J Emerg Med. Biochemical testing for neuroendocrine tumors. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
Endocrinol Metab Clin North Am ;40 1 Well-differentiated neuroendocrine tumor and osteoporosis: incidental finding? Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide.
Archive of Clinical Cases
Acta Oncol. Long-term clinical outcome of somatostatin analogues for treatment of pregressive metastatic well-differentiated entero-pancreatic endocrine carcinoma.
Ann Oncol. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.